Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) General Information
Description
The worldwide rights to a portfolio of therapeutic monoclonal antibodies intended to provide potential treatment of PAH.
Contact Information
Corporate Office
- 2000 Auburn Drive
- Suite 200
- Beachwood, OH 44122
- United States
Corporate Office
- 2000 Auburn Drive
- Suite 200
- Beachwood, OH 44122
- United States
Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) FAQs
-
Where is Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) headquartered?
Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) is headquartered in Beachwood, OH.
-
What industry is Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) in?
Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies)’s primary industry is Drug Discovery.
-
Is Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) a private or public company?
Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) is a Private company.
-
What is Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies)’s current revenue?
The current revenue for Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) is .
-
Who are Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies)’s investors?
Allinaire Therapeutics has invested in Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies).
-
When was Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) acquired?
Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) was acquired on 02-May-2022.
-
Who acquired Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies)?
Allinaire Therapeutic ( Worldwide Rights To a Portfolio of Therapeutic Monoclonal Antibodies) was acquired by Chiesi Farmaceutici.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process